05:57 PM EDT, 05/14/2024 (MT Newswires) -- Nanobiotix ( NBTX ) said Tuesday the US Food and Drug Administration accepted the protocol for a randomnized phase 2 study evaluating NBTXR3 for the treatment of patients with stage 3, unresectable non-small cell lung cancer.

The biotechnology company also said the global trial sponsor, Johnson & Johnson Enterprise Innovation, a unit of Johnson & Johnson (JNJ), has submitted an investigational new drug application to support the trial.

Price: 7.30, Change: +0.01, Percent Change: +0.14